Compare NEOG & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | STOK |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1995 | 2019 |
| Metric | NEOG | STOK |
|---|---|---|
| Price | $11.87 | $24.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $14.00 | ★ $46.46 |
| AVG Volume (30 Days) | ★ 3.9M | 696.2K |
| Earning Date | 10-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.20 | 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $870,400,000.00 | $184,420,000.00 |
| Revenue This Year | $1.47 | N/A |
| Revenue Next Year | N/A | $39.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $5.37 | $20.32 |
| 52 Week High | $14.26 | $40.22 |
| Indicator | NEOG | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 29.76 |
| Support Level | $8.68 | N/A |
| Resistance Level | $12.55 | $33.61 |
| Average True Range (ATR) | 0.71 | 1.29 |
| MACD | -0.16 | -0.20 |
| Stochastic Oscillator | 1.90 | 17.81 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.